Kabos Peter, Ehtesham Moneeb, Black Keith L, Yu John S
Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Ste. 800E, 8631 W 3rd St, Los Angeles, CA 90048, USA.
Expert Opin Biol Ther. 2003 Aug;3(5):759-70. doi: 10.1517/14712598.3.5.759.
The discovery of neural stem cells (NSCs) has changed our long-held view that the adult mammalian central nervous system (CNS) is postmitotic and lacks the capability for self-repair. The role of NSCs in physiological and pathological processes in the brain is slowly emerging. We are now able to isolate, expand, genetically engineer and transplant NSCs. An important characteristic of NSCs, not fully understood so far, is their migratory ability and their tropism to brain pathology. The migratory ability of NSCs and their capacity to differentiate into all neural phenotypes gives us a potentially powerful tool for the treatment of both diffuse and localised neurologic disorders. The delivery of gene products by NSCs to specific sites in the CNS can maximise the efficiency of delivery and minimise the unwanted exposure of surrounding intact tissue. Here, the recent preclinical advances in the use of NSCs for the delivery of therapeutic products are reviewed, in particular the employment of their migratory potential and the homing ability to pathology in the nervous system.
神经干细胞(NSCs)的发现改变了我们长期以来所持的观点,即成年哺乳动物中枢神经系统(CNS)处于有丝分裂后状态且缺乏自我修复能力。NSCs在大脑生理和病理过程中的作用正逐渐显现出来。我们现在能够分离、扩增、进行基因工程改造并移植NSCs。NSCs的一个重要特征,即其迁移能力及其对脑病理的趋向性,目前尚未被完全理解。NSCs的迁移能力以及它们分化为所有神经表型的能力,为我们提供了一种潜在的强大工具,用于治疗弥漫性和局灶性神经系统疾病。通过NSCs将基因产物递送至CNS中的特定部位,可以最大限度地提高递送效率,并将周围完整组织的不必要暴露降至最低。在此,对使用NSCs递送治疗性产品的近期临床前进展进行综述,特别是利用它们的迁移潜能和对神经系统病理的归巢能力。